The long-term effect of axillary pathologic complete response (pCR) on survival among women with breast cancer treated with primary systemic chemotherapy (PST) is unknown.
breast conservation surgery. Primary systemic chemotherapy has an additional advantage in that it allows response to be assessed clinically in vivo throughout treatment and pathologically after surgery. Several studies have shown that patients treated with PST who achieve a pathologic complete response (pCR) in the breast and axilla have superior longterm outcomes. [2] [3] [4] The presence of axillary lymph node metastases at diagnosis is an important prognostic factor in breast cancer. A prior study from our institution examined 403 patients with cytologically confirmed axillary metastases, 89 of whom achieved an axillary pCR after systemic therapy. Patients who achieved an axillary pCR had significantly improved 5-year OS and RFS relative to patients who did not. 4 Over the past several years, more data have emerged regarding the rates of pCR in the breast and axilla in different breast cancer subtypes after PST with different chemotherapy backbones. Of particular interest is the response to human epidermal growth factor receptor 2 (HER2)-targeted therapy in HER2-positive breast cancers. There have been several reports of high pCR rates, ranging from 40% to 74%, with HER2-targeted therapy plus cytotoxic chemotherapy. [5] [6] [7] Previous studies have shown that pCR in the axillary nodes has a greater effect on survival than the response to chemotherapy in the primary breast tumor. 4, 7, 8 A prior study from our group showed that among patients with axillary pCR, 5-year RFS did not differ between patients with breast pCR and those with residual disease in the breast, with the hypothesis that residual tumor cells in the breast do not have metastatic potential. 4 In the study reported herein, we sought to determine the effect of axillary pCR on 10-year OS and RFS in patients with breast cancer and cytologically confirmed axillary metastases at diagnosis. This study is an expansion of the prior study from our group 4 and includes all patients with stage II to III breast cancer with cytologically confirmed axillary metastases treated with PST at 1 institution.
Methods
We performed a retrospective review of the Breast Medical Oncology institutional database at the University of Texas MD An- Cancer TNM staging classification) nuclear grade, adjuvant therapies (additional chemotherapy, radiation therapy, and endocrine therapy), and class of PST used (anthracycline-based only, taxane-based only, or containing both an anthracycline and a taxane). Breast pCR (T0 disease) was defined as no residual invasive carcinoma; residual intraductal carcinoma alone was classified as T0. Race and ethnicity were collected by selfreport by questionnaire at the time of new patient visit and are included to demonstrate the diversity of patients seen at our institution. The institutional review board of the University of Texas MD Anderson Cancer Center approved this study. Informed consent was waived due to the retrospective nature of this study. Patient characteristics were summarized, and the axillary pCR and residual axillary disease groups were compared using χ 2 test or t test, as appropriate. Overall survival was measured from the date of definitive surgery (after the completion of PST) to the date of death or last follow-up. Recurrencefree survival was measured from the date of definitive surgery (after the completion of PST) to the date of first documented local or distant recurrence or last follow-up, or to death, whichever came first. The Kaplan-Meier product-limit method was used to estimate the survival outcomes of patients by groups; groups were compared using the log-rank statistic. Subset analyses were carried out within the group of patients with HER2-positive breast cancers who received HER2-targeted therapy.
Cox proportional hazards models were fit to determine the association of axillary pCR or residual axillary tumor with survival outcomes after adjustment for other patient and disease characteristics. Variables that were significant on univariate log-rank test were candidates for the multivariable models. A backward selection was used to determine variables were retained in the final models. Multivariate analysis was also performed within the subset of patients with HER2-positive tumors. Results are expressed in hazard ratios and 95% CIs. P < .05 was considered statistically
At a Glance
• This is a retrospective analysis of the effect of axillary pathologic complete response (pCR) on 10-year overall survival (OS) and relapse-free survival (RFS) among women with cytologically confirmed axillary metastases treated with primary systemic chemotherapy at 1 institution.
• Axillary pCR was associated with 10-year RFS of 83% and 10-year OS of 85%; for patients with residual axillary disease, 10-year RFS was 58% and 10-year OS was 55%.
• Among patients with axillary pCR, 10-year OS rates were 90% for those with pCR in the breast and 73% for those with residual breast disease.
• High rates of axillary pCR were observed in patients receiving human epidermal growth factor receptor 2 (HER2)-targeted therapy for HER2-positive disease, and survival rates were similar to those of other subtypes with regard to axillary response. Of the clinicopathologic parameters examined, the factors associated with axillary pCR were triple-negative and HER2-positive breast cancer (P < .001), lower clinical and pathologic T stage (P = .002), pCR in the breast (P < .001), and higher grade (P < .001). Patients with clinical N3 disease had higher rates of axillary pCR than patients with N1 or N2 disease (P = .003). Two hundred eighty-five of the 1536 patients for whom pathologic stage was available (18.6%) achieved a pCR in both the breast and axilla.
Results

Patient Characteristics and Associations With pCR
Nearly three-quarters of the 1600 patients in this analysis received PST that included both a taxane and an anthracycline (1147 [73.5%] of the 1561 patients for whom chemotherapy data were available); for these patients, the rate of axillary pCR was 32.0%. Axillary pCR rates were lower for patients treated with a taxane without an anthracycline (23.7%) or an anthracycline without a taxane (19.0%). Most patients (84.8%) underwent adjuvant radiation, and 56.6% of patients received adjuvant endocrine therapy.
Hormone receptor and/or HER2 status was unknown for 254 patients. Among the remaining patients, rates of axillary pCR were 16.4% for HR-positive/HER2-negative tumors, 40.8% for HR-positive/HER2-positive tumors, 40.8% for HR-negative/ HER2-negative tumors, and 55.2% for HR-negative/HER2-positive tumors. Rates of pCR in both breast and axilla were 7.3% for HR-positive/HER2-negative tumors, 28.8% for HR-positive/ HER2-positive tumors, 28.7% for HR-negative/HER2-negative tumors, and 40.9% for HR-negative/HER2-positive tumors.
Three hundred thirty-eight patients (25.1%) had HER2-positive tumors; treatment regimen was known for 336 patients. Many of these patients were treated before the approval of trastuzumab in the adjuvant setting; only 149 patients (44.3%) received HER2-targeted therapy (predominantly trastuzumab; 2 patients received lapatinib on protocol). Among patients with HER2-positive tumors, 67.1% of patients who received HER2-targeted therapy achieved an axillary pCR, compared with 32.6% of those who did not receive HER2-targeted therapy (P < .001).
Survival Estimates
Median (range) follow-up time among all women was 79 (5-277) months. At the time of this analysis, 480 women (30.0%) had died, and 546 (34.1%) had experienced a recurrence. Of the 546 patients with a recurrence, 37 (6.8%) had locoregional recurrence only, 360 (65.9%) had distant relapse only, and 149 (27.3%) developed both locoregional and distant relapse.
Five-year and 10-year OS and RFS rates by patient characteristics are available in eTable 2 in the Supplement. For the overall cohort, the 5-year OS and RFS rates were 79% (95% CI, 77%-81%) and 67% (95% CI, 65%-69%), respectively; the 10-year OS and RFS rates were 64% (95% CI, 61%-67%) and 58% (95% CI, 55%-60%), respectively.
Kaplan-Meier OS and RFS curves by the disease status of the axilla after PST are shown in Figure 1 . Five-year OS rates were 91% (95% CI, 88%-93%) and 75% (95% CI, 72%-77%), respectively, for patients with axillary pCR and residual axillary disease; 10-year OS rates were 84% (95% CI, 79%-88%) and 57% (95% CI, 54%-61%), respectively (P < .001). Five-year RFS rates were 84% (95% CI, 80%-87%) and 60% (95% CI, 58%-63%), respectively, for patients with axillary pCR and residual axillary disease; 10-year RFS rates were 79% (95% CI, 74%-83%) and 50% (95% CI, 46%-53%), respectively (P < .001).
Kaplan-Meier OS and RFS curves by disease status of the axilla and the breast after PST are shown in Figure 2 . Ten-year OS rates were 90% (95% CI, 84%-94%) and 72% (95% CI, 61%-80%), respectively, for patients with axillary and breast pCR and patients with axillary pCR but residual breast disease (P < .001); 10-year RFS rates were 85% (95% CI, 79%-90%) and 66% (95% CI, 56%-74%), respectively (P < .001). Ten-year OS rates were 66% (95% CI, 56%-74%) and 56% (95% CI, 52%-60%), respectively, for patients with residual axillary disease but breast pCR and patients with residual axillary and breast disease (P = .02); 10-year RFS rates were 56% (95% CI, 46%-65%) and 49% (95% CI, 46%-53%), respectively (P = .04).
For the subset of all patients with HER2-positive tumors (n = 339), 10-year survival estimates were slightly better than those of the overall cohort: 10-year OS and RFS rates were 68.1% (95% CI, 61.3%-74.0%]) and 61.3% (95% CI, 54.8%-67.1%), respectively. Among the 336 patients with HER2-positive tumors for whom treatment regimen was known, patients who received HER2-targeted therapy had higher survival rates than patients who did not receive HER2-targeted therapy: 10-year OS rates were 77% (95% CI, 52%-90%) and 62% (95% CI, 54%-69%), respectively (P < .001), and 10-year RFS rates were 70% (95% CI, 49%-84%) and 53% (95% CI, 46%-61%), respectively (P < .001). Among patients with HER2-positive tumors who received HER2-targeted therapy, those who achieved an axillary pCR had higher survival rates than those with residual axillary disease: the 10-year OS estimates were 92% (95% CI, 84%-96%) and 57% (95% CI, 20%-82%), respectively (P = .003), and the 10-year RFS estimates were 89% (95% CI, 81%-94%) and 44% (95% CI, 18%-68%), respectively (P < .001) (Figure 3 ).
Multivariable Modeling
The Table summarizes the multivariable Cox proportional hazards models for OS and RFS, adjusted for axillary pCR vs residual axillary disease, age, race, breast cancer subtype, clinical T stage, breast pCR vs residual breast disease, grade, and adjuvant radiation and endocrine therapy in all patients. Compared with women who achieved an axillary pCR, those with residual axillary disease had a 3-fold increase in the risk of death (hazard ratio, 3.02 [95% CI, 2.14-4.27]; P < .001) and a 3.1-fold increase in the risk of recurrence (hazard ratio, 3.10 [95% CI, 2.31-4.15]; P < .001). With respect to OS, the following factors were associated with an increased risk of death: higher clinical T stage, residual disease in the breast, and grade 3. Receipt of adjuvant radiation or endocrine therapy was protective (P < .001 for both). Similar results were obtained for RFS.
Within the subset of all patients with HER2-positive tumors, compared with patients with an axillary pCR, patients with residual axillary disease had a 3.49-fold increase in the risk of death (hazard ratio 
Discussion
We report on a large cohort of patients with cytologically confirmed axillary lymph node metastases who underwent PST. We found associations between axillary pCR and triplenegative and HER2-positive disease, high grade, and lower clinical and pathologic T stage. Patients with axillary pCR had better OS and RFS than patients with residual axillary disease, both overall and in the subset of patients with HER2-positive disease treated with HER2-targeted therapy. Furthermore, among patients with axillary pCR, those with breast pCR had better OS and RFS than those with residual breast disease. Our finding that 18.6% of patients had no residual invasive carcinoma in the breast or axilla after PST is similar to those from other studies. 9 Our finding that 28.4% of patients had an axillary pCR is also consistent with prior analyses. Hennessy et al 4 reported an axillary pCR rate of 22% in patients treated with PST, and earlier studies showed axillary pCR rates after PST of 23% to 40%. 2, 4, [10] [11] [12] Many recent studies have examined rates of pCR in both the breast and axilla after PST in patients with HER2-positive tumors; in this population, pCR rates of 39% to 60.6% have been reported. [5] [6] [7] 13, 14 In our study, the axillary pCR rate in patients who received HER2-targeted PST was 67.1%, consistent with other reported axillary pCR rates in this subset.
6,7
In our study, high rates of axillary pCR after PST were seen despite poor primary tumor-related prognostic features, such as high grade and negative HR status. The survival differences observed between patients in whom PST eradicated axillary lymph node metastases and patients with residual axillary disease support the use of axillary pCR as a marker for longterm outcome. The definition of "overall pCR" should include axillary nodal pCR, in keeping with recent international group recommendations. 15 The addition of trastuzumab for treatment of patients with HER2-positive disease has had a profound positive effect on the rates of axillary pCR and the long-term outcomes for these patients. 16, 17 Further benefit is seen when trastuzumab is combined with other HER2-targeting agents, such as lapatinib or pertuzumab. 18, 19 Continued advances in the development and study of targeted agents with better toxicity profiles than those of traditional cytotoxic chemotherapy drugs may further improve pCR rates in all subtypes of breast cancer. Genomic and proteomic profiling may assist in predicting which patients may achieve a pCR with use of only a taxane or an anthracycline so as to avoid overtreatment and its cost and toxic effects.
We found that patients with a pCR in the axilla but residual disease in the breast had better survival than patients with a pCR in the breast but residual disease in the axilla, in agreement with findings from previous studies by our group and others. 4, 8 This finding suggests that after PST, clearance of axillary metastases is more important than clearance of disease in the breast. This finding may relate to the inherent biological characteristics and increased metastatic potential of axillary metastases. However, in contrast to our prior analysis, 4 our present analysis showed that among patients with axillary pCR, patients with a breast pCR had better survival than those with residual disease in the breast. This difference in findings between our previous analysis and our present analysis is likely due to an increased number of patients with discordant pathologic findings in the breast and axilla and therefore increased power to detect survival differences related to the status of residual disease in the breast.
A higher proportion of patients in the present study (73.5%) than in a prior analysis (35.7%) received third-generation chemotherapy 4 ; in this study, patients who received both an anthracycline and a taxane were more likely to achieve an axillary pCR than were patients who received only one. However, nearly one-quarter of patients who received a taxane without an anthracycline achieved an axillary pCR, suggesting that treatment without an anthracycline might be sufficient for a subset of patients. Such treatment would spare patients the toxic effects of anthracycline therapy.
In the present study, the risk of relapse after 5 years was small for patients who achieved an axillary pCR: the difference between the 5-year and 10-year RFS rates was 5 percentage points (84% vs 79%). Patients who did not have an axillary pCR had a higher risk of relapse even after 5 years (5-year RFS rate, 60%; 10-year RFS rate, 50%).
If clearance of disease in the axillary nodes with PST is associated with a better prognosis, then it may be desirable to determine which patients do not require axillary lymph node dissection after PST. Two recent trials, SENTINA 18 and needed to determine what clinical and radiologic tools might enable patients who achieve an axillary pCR after PST to avoid axillary dissection with its complications and morbidity. At our institution, we currently place a marker in the affected axillary node prior to PST to facilitate targeting of the sentinel node after chemotherapy and thereby mitigate the risk of false-negative findings on sentinel lymph node biopsy.
All of the patients included in this analysis had cytologic confirmation of axillary lymph node metastases prior to PST, and pathologic examination of the axillary nodes after surgery was performed at our institution. However, our study does have some limitations. This is a retrospective analysis of patients treated at a single center, which limits generalizability. Whereas the chemotherapeutic agents used were recorded, the precise dosages and numbers of cycles were not. Some of the patients included in the analysis were treated on protocol, whereas others were treated according to standards for our institution or were treated at other institutions. Stratification based on the chemotherapy backbone used (ie, anthracycline and/or taxane) was possible, but further analysis comparing specific regimens was not possible. Additionally, missing data such as data on HR and HER2 status could have affected our findings. Finally, the patients in this study received a diagnosis over a long period, although most patients were treated in 2000 or later. Treatment modalities and strategies have changed over the time frame under study, which may have affected our results.
Conclusions
Our findings indicate that patients who achieve a pCR in the axilla after PST have better long-term clinical outcomes than patients with residual disease in the axilla. Molecular-based correlates in future protocols may enhance our understanding of the biologic differences between the primary tumor in the breast and axillary lymph node metastases. Further studies are needed to determine whether patients with residual disease after PST, particularly in the axillary lymph nodes, may benefit from further therapy after surgery to reduce the risk of relapse and improve survival.
